A Phase 1/2 Study of ARQ 092 (Miransertib) in Subjects With PIK3CA-related Overgrowth Spectrum (PROS) and Proteus Syndrome (PS) (MOSAIC)
Phase of Trial: Phase I/II
Latest Information Update: 20 Nov 2019
Price : $35 *
At a glance
- Drugs Miransertib (Primary)
- Indications Growth disorders; Proteus syndrome
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms MOSAIC
- Sponsors ArQule
- 02 Oct 2019 According to an ArQule media release, first patient has been dosed in the registrational part of the trial.
- 15 Aug 2019 Planned number of patients changed from 40 to 85.
- 15 Aug 2019 Planned End Date changed from 1 Jun 2020 to 30 Jun 2023.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History